Imatinib and altered bone and mineral metabolism.
Tournis
Symeon
S
Lyritis
George P
GP
D001549:Benzamides; D015415:Biomarkers / Q000097:blood; D001800:Blood Specimen Collection / Q000592:standards; D001842:Bone and Bones / Q000378:metabolism; D002118:Calcium / Q000097:blood; D006801:Humans; D017674:Hypophosphatemia / Q000139:chemically induced*; D000068877:Imatinib Mesylate; D015675:Osteocalcin / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood*; D010879:Piperazines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood
D001549:Benzamides; D015415:Biomarkers; D010281:Parathyroid Hormone; D010710:Phosphates; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D015675:Osteocalcin; D014807:Vitamin D; D000068877:Imatinib Mesylate; C104450:25-hydroxyvitamin D; D002118:Calcium